Aaron Goodman: The way we treat multiple myeloma will bankrupt the system and further enrich pharma.

According to Aaron Goodman on Twitter/X:

“The way we treat multiple myeloma will bankrupt the system and further enrich pharma. Soon we will be moving CART and BiTES to earlier lines (even asymptomatic smoldering) based off a surrogate endpoints. Our patients and society deserve better.”

Source: Aaron Goodman/Twitter

Aaron Goodman, MD is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.